Penumbra Inc PEN
Penumbra Inc (PEN) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $1.4B at a 12.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.45 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-07-06 | Evercore ISI Group | Outperform (main) |
| 2026-06-11 | RBC Capital | Sector Perform (reit) |
| 2026-05-07 | Citigroup | Neutral (main) |
| 2026-05-07 | Evercore ISI Group | Outperform (main) |
| 2026-02-26 | Evercore ISI Group | Outperform (main) |
| 2026-01-20 | RBC Capital | Sector Perform (down) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.566 |
| Retained earnings / assets | 0.13 |
| EBIT / assets | 0.104 |
| Equity / liabilities | 3.579 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PEN | Penumbra Inc | 6/9 | 8.59 | 70.1 | +17.5% |
| HAE | HAEMONETICS CORP | 7/9 | 2.85 | 36.1 | -2% |
| MMSI | MERIT MEDICAL SYSTEMS INC | 7/9 | 4.93 | 33.3 | +11.8% |
| IART | INTEGRA LIFESCIENCES HOLDINGS CORP | 5/9 | 1.17 | — | +1.5% |
| EMBC | Embecta Corp. | 6/9 | 1.99 | 2.2 | -3.8% |
| TNDM | TANDEM DIABETES CARE INC | 3/9 | -3.04 | — | +7.9% |
| INSP | Inspire Medical Systems, Inc. | 6/9 | 9.88 | 9.1 | +13.6% |
About Penumbra Inc
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
FAQ
Is PEN financially healthy?
Penumbra Inc's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does PEN pay a dividend?
No, Penumbra Inc does not currently pay a dividend.
How profitable is PEN?
In FY2025, Penumbra Inc had a net margin of 12.7% and a return on equity of 12.4%.
Is PEN overvalued or undervalued?
Penumbra Inc trades at about 72.3× trailing earnings — below its 10-year norm (10-year range 79.2×–1614.4×, median 535.0×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for PEN?
The average Wall-Street price target for Penumbra Inc is $361.83, about 10.8% above the recent price, from 12 analysts (consensus: hold).
Is PEN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Penumbra Inc: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 70.1×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.